Skip to main content
SpringerLink
Log in

Fungal Infections in the Immunocompromised Host

  • Chapter
Clinical Approach to Infection in the Compromised Host

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Romani L, Howard DH: Mechanisms of resistance to fungal infections. Curr Opin Immunol 7:517–523, 1995.

    Article  CAS  PubMed  Google Scholar 

  2. Romani L: The T cell response against fungal infections. Curr Opin Immunol 9:484–490, 1997.

    Article  CAS  PubMed  Google Scholar 

  3. Williamson EC, Millar MR, Steward CJ, et al: Infections in adults undergoing unrelated donor bone marrow transplantation. Br J Haematol 104:560–568, 1999.

    Article  CAS  PubMed  Google Scholar 

  4. Walsh TJ, Hiemenz J, Pizzo PA: Editorial response: Evolving risk factors for invasive fungal infections—All neutropenic patients are not the same. Clin Infect Dis 18:793–798, 1994.

    CAS  PubMed  Google Scholar 

  5. Sable C, Donowitz G: Infections in bone marrow transplant recipients. Clin Infect Dis 18:273–284, 1994.

    CAS  PubMed  Google Scholar 

  6. LaRocco MT, Burgert SJ: Infection in the bone marrow transplant recipient and role of the microbiology laboratory in clinical transplantation. Clin Microbiol Rev 10:277–297, 1997.

    CAS  PubMed  Google Scholar 

  7. Jantunen E, Ruutu P, Niskanen L, et al: Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant 19:801–808, 1997.

    Article  CAS  PubMed  Google Scholar 

  8. Perfect JR, Schell WA: The new fungal opportunists are coming. Clin Infect Dis 22(Suppl 2):S112–S118, 1996.

    PubMed  Google Scholar 

  9. Hazen KC: New and emerging yeast pathogens. Clin Microbiol Rev 8:462–478, 1995.

    CAS  PubMed  Google Scholar 

  10. Wade JJ, Rolando N, Hayllar K, et al: Bacterial and fungal infections after liver transplantation: An analysis of 284 patients. Hepatology 21:1328–1336, 1995.

    CAS  PubMed  Google Scholar 

  11. Patel R, Portela D, Badley AD, et al: Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation. Transplantation 62:926–934, 1996.

    CAS  PubMed  Google Scholar 

  12. Collins LA, Samore MH, Roberts MS, et al: Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis 170:644–652, 1994.

    CAS  PubMed  Google Scholar 

  13. Imam N, Carpenter CCJ, Mayer KH, et al: Hierarchical pattern of mucosal Candida infections in HIV-seropositive women. Am J Med 89:142–146, 1990.

    Article  CAS  PubMed  Google Scholar 

  14. Denning DW, Follansbee SE, Scolaro M, et al: Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med 324:654–662, 1991.

    CAS  PubMed  Google Scholar 

  15. Martins MD, Lozano-Chiu M, Rex JH: Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients. Clin Infect Dis 27:1291–1294, 1998.

    CAS  PubMed  Google Scholar 

  16. Bow EJ, Laverdiere M, Lussier N, Rotstein C: Antifungal prophylaxis in neutropenia cancer patients: A meta-analysis of randomized controlled trials. Abst #1516. In Abstracts of the 41st Annual Meeting of the American Society of Hematology, New Orleans, LA, 1999.

    Google Scholar 

  17. Goodman JL, Winston DJ, Greenfield RA, et al: A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 326:845–851, 1992.

    CAS  PubMed  Google Scholar 

  18. Slavin MA, Osborne B, Adams R, et al: Efficacy and safety of fluconazole prophylaxis for fungal infections after bone marrow transplantation—A prospective, randomized, double-blind study. J Infect Dis 171:1545–1552, 1995.

    CAS  PubMed  Google Scholar 

  19. Winston DJ, Chandrasekar PH, Lazarus HM, et al: Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Ann Intern Med 118:495–503, 1993.

    CAS  PubMed  Google Scholar 

  20. Rotstein C, Bow EJ, Laverdiere M, et al: Randomized placebocontrolled trial of fluconazole prophylaxis for neutropenic cancer patients: Benefit based in purpose and intensity of cytotoxic therapy. Clin Infect Dis 28:331–340, 1999.

    CAS  PubMed  Google Scholar 

  21. Gubbins PO, Bowman JL, Penzak SR: Antifungal prophylaxis to prevent invasive mycoses among bone marrow transplant recipients. Pharmacotherapy 18:549–564, 1998.

    CAS  PubMed  Google Scholar 

  22. Böhme A, Karthaus M, Hoelzer D: Antifungal prophylaxis in neutropenic patients with hematologic malignancies: Is there a real benefit? Chemotherapy 45:224–232, 1999.

    PubMed  Google Scholar 

  23. Schaffner A, Schaffner M: Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J Infect Dis 172:1035–1041, 1995.

    CAS  PubMed  Google Scholar 

  24. Alangaden G, Chandrasekar PH, Bailey E, et al: Antifungal prophylaxis with low-dose fluconazole during bone marrow transplantation. Bone Marrow Transplant 14:919–924, 1994.

    CAS  PubMed  Google Scholar 

  25. Guinet R, Marlier R: tSensibilite comparee des levures aux ketoconazole, itraconazole et fluconazole en micromethode standardisee en milieu liquide. Pathol Biol 38:575–578, 1990.

    CAS  PubMed  Google Scholar 

  26. Wingard JR, Merz WG, Rinaldi MG, et al: Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 325:1274–1277, 1991.

    CAS  PubMed  Google Scholar 

  27. Marr KA, Seidel K, White TC, Bowden R: Candidemia in allogeneic blood and bone marrow transplant recipients: Evolution of risk factors after adoption of prophylactic fluconazole, J Infect Dis 181:309–316, 2000.

    Article  CAS  PubMed  Google Scholar 

  28. Tricot G, Joosten E, Boogaerts MA, et al: Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: Preliminary results of two nonrandomized studies. Rev Infect Dis 9(Suppl 1):S94–S99, 1987.

    PubMed  Google Scholar 

  29. Böhme A, Just-Nübling G, Bergmann L, et al: Itraconazole for prophylaxis of systemic mycoses in neutropenic patients with haematological malignancies. J Antimicrob Chemother 38:953–961, 1996.

    PubMed  Google Scholar 

  30. Glasmacher A, Molitor E, Hahn C, et al: Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukemia. Leukemia 12:1338–1343, 1998.

    Article  CAS  PubMed  Google Scholar 

  31. Vreugdenhil G, Van Dijke BJ, Donnelly JP, et al: Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double-blind, placebo controlled study. Leuk Lymphoma 11:353–358, 1993.

    CAS  PubMed  Google Scholar 

  32. Huijgens PC, Simoons-Smit AM, Van Loenen AC, Prooy E: Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology. Clin Pathol 52:376–380, 1999.

    CAS  Google Scholar 

  33. Lamy T, Bernard M, Courtois A, et al: Prophylactic use of itraconazole for the prevention of invasive pulmonary aspergillosis in high risk neutropenic patients. Leuk Lymphoma 30:163–174, 1998.

    CAS  PubMed  Google Scholar 

  34. Menichetti F, Del Favero A, Martino P, et al: Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: A randomized, placebo-controlled, double-blind, multicenter trial. Clin Infect Dis 28:250–255, 1999.

    CAS  PubMed  Google Scholar 

  35. Morgenstern GR, Prentice AG, Prentice HG, et al: A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. Br J Haematol 105:901–911, 1999.

    Article  CAS  PubMed  Google Scholar 

  36. O’Donnell MR, Schmidt GM, Tegtmeier BR, et al: Prediction of systemic fungal infection in allogeneic marrow recipients: Impact of amphotericin prophylaxis in high-risk patients. J Clin Oncol 12:827–834, 1994.

    Google Scholar 

  37. Perfect JR, Klotman ME, Gilbert CC, et al: Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 165:891–897, 1992.

    CAS  PubMed  Google Scholar 

  38. Bodey GP, Anaissie EJ, Elting LS, et al: Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. Cancer 73:2099–2106, 1994.

    CAS  PubMed  Google Scholar 

  39. Wolff SN, Fay J, Stevens D, el al: Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: A study of the North American Marrow Transplant Group. Bone Marrow Transplant 25:853–859, 2000.

    Article  CAS  PubMed  Google Scholar 

  40. Hiemenz JW, Walsh TJ: Lipid formulations of amphotericin B: Recent progress and future directions. Clin Infect Dis 22:S133–S144, 1996.

    CAS  PubMed  Google Scholar 

  41. Walsh TJ, Finberg RW, Arndt C, et al: Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 340:764–771, 1999.

    Article  CAS  PubMed  Google Scholar 

  42. Tollemar J, Ringdùn O, Andersson S, et al: Randomized double-blind study of liposomal amphotericin B (AmBisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 12:577–582, 1993.

    CAS  PubMed  Google Scholar 

  43. Kelsey SM, Goldman JM, McCann S, et al: Liposomal amphotercin (AmBisome) on the prophylaxis of fungal infections in neutropenic patients: A randomized, double-blind, placebo-controlled study. Bone Marrow Transplant 23:163–168, 1999.

    Article  CAS  PubMed  Google Scholar 

  44. Timmers GJ, Zweegman S, Simoons-Smit AM, et al: Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: Data of a prematurely stopped clinical trial. Bone Marrow Transplant 25: 879–884, 2000.

    Article  CAS  PubMed  Google Scholar 

  45. Lumbreras C, Cuervas-Mons V, Jara P, et al: Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. J Infect Dis 174:583–588, 1996.

    CAS  PubMed  Google Scholar 

  46. Winston DJ, Pakrasi A, Busuttil RW: Prophylactic fluconazole in liver transplant recipients —A randomized, double-blind, placebo-controlled trial. Ann Intern Med 131:729–737, 1999.

    CAS  PubMed  Google Scholar 

  47. Linden P, Kramer LP, Mazariegos G, et al: Low-dose amphotericin B for the prophylaxis of serious Candida infections in high-risk liver recipients. Abst J47. In Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996, p. 227.

    Google Scholar 

  48. Tollemar J, Höckerstedt K, Ericzon B-G, et al: Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo-controlled study. Transplantation 59:45–50, 1995.

    CAS  PubMed  Google Scholar 

  49. Colby WD, Sharpe MD, Ghent CN, et al: Efficacy of itraconazole prophylaxis against systemic fungal infection in liver transplant recipients. Abst 1650. In Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1999.

    Google Scholar 

  50. Nadeem I, Yeldandi V, Sheridan P, et al: Efficacy of itraconazole prophylaxis for aspergillosis in lung transplant recipients. In Program and Abstracts of the 32nd Annual Meeting of the Infectious Disease Society of America, p. 58A, 1994.

    Google Scholar 

  51. Calvo V, Borro JM, Morales P, et al: Antifungal prophylaxis during the early postoperative period of lung transplantation. Chest 115:1301–1304, 1999.

    Article  CAS  PubMed  Google Scholar 

  52. Lau CL, Palmer SM, D’Amico TA, et al: Lung transplantation at Duke University Medical Center. Clin Transplant 327–340, 1998.

    Google Scholar 

  53. Barchiesi F, Arzeni D, Fothergill AW, et al: In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens. Antimicrob Agents Chemother 44:226–229, 2000.

    CAS  PubMed  Google Scholar 

  54. Kirkpatrick WR, McAtee RK, Fothergill AW, et al: Efficacy of SCH56592 in a rabbit model of invasive aspergillosis. Antimicrob Agents Chemother 44:780–782, 2000.

    CAS  PubMed  Google Scholar 

  55. Ikeda F, Wakai Y, Matsumoto S, et al: Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob Agents Chemother 44: 614–618, 2000.

    Article  CAS  PubMed  Google Scholar 

  56. Pizzo PA, Ribichaud KJ, Gill FA, Witebsky FG: Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 72:101–111, 1982.

    Article  CAS  PubMed  Google Scholar 

  57. Krick JA, Remington JS: Opportunistic invasive fungal infections in patients with leukaemia or lymphoma. Clin Haematol 5:249–310, 1976.

    CAS  PubMed  Google Scholar 

  58. Fraser DW, Ward JI, Ajello L, Plikaytis BD: Aspergillosis and other systemic mycoses: The growing problem. JAMA 242:1631–1635, 1979.

    Article  CAS  PubMed  Google Scholar 

  59. Pennington JE: Successful treatment of Aspergillus pneumonia in hematologic neoplasia. N Engl J Med 295:426–427, 1976.

    CAS  PubMed  Google Scholar 

  60. Aisner J, Wiernik PH, Schimpf SC: Treatment of invasive aspergillosis: Relation of early diagnosis and treatment to response. Ann Intern Med 86:539–543, 1977.

    CAS  PubMed  Google Scholar 

  61. Stein RS, Kayser J, Flexner JM: Clinical value of empirical am-photericin B in patients with acute myelogenous leukemia. Cancer 50:2247–2251, 1982.

    CAS  PubMed  Google Scholar 

  62. European Organization for Research on Treatment of Cancer International Antimicrobial Therapy Cooperative Group: Empiric antifungal therapy in febrile granulocytopenic. Am J Med 86:668–672, 1989.

    Google Scholar 

  63. Prentice HG, Hann IM, Herbrecht R, et al: A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 98:711–718, 1997.

    Article  CAS  PubMed  Google Scholar 

  64. Wingard JR, White MH, Anaissie EJ, Rafailli JT: A randomized double-blind safety study of AmBisome and Abelcet in febrile neutropenic patients. Proc 9th Focus Fungal Infect Meet 98:711–718, 1999.

    Google Scholar 

  65. White MH, Bowden RA, Sandler ES, et al: Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 27:296–302, 1998.

    CAS  PubMed  Google Scholar 

  66. Viscoli C, Castagnola E, Van Lint MT, Moroni C: Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granuolytopenic cancer patients: A pragmatic, multicentre, prospective and randomized clinical trial. Eur J Cancer 32A:814–820, 1996.

    CAS  PubMed  Google Scholar 

  67. Winston DJ, Hathorn JW, Schuster MG, et al: A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 108:282–289, 2000.

    Article  CAS  PubMed  Google Scholar 

  68. Malik IA, Moid I, Aziz A, Kham S: A randomized comparison of fluconazole with amphtericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. Am J Med 105:478–483, 1998.

    Article  CAS  PubMed  Google Scholar 

  69. Boogaerts M, Garber G, Winston D, Reboli A: Itraconazole compared with amphotericin B as empirical therapy for persistent fever of unknown origin in neutropenic patients. Bone Marrow Transplant 23:S111, 1999.

    Google Scholar 

  70. Sheehan DJ, Hitchcock CA, Sibley CM: Current and emerging azole antifungal agents. Clin Microbiol Rev 12:40–79, 1999.

    CAS  PubMed  Google Scholar 

  71. Pfaller MA, Marco F, Messer SA, Jones RN: In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis 30:251–255, 1998.

    CAS  PubMed  Google Scholar 

  72. Marina NM, Flynn PM, Rivera GK, Hughes WT: Candida tropicalis and Candida albicans fungemia in children with leukemia. Cancer 68:594–599, 1991.

    CAS  PubMed  Google Scholar 

  73. Silverman RA, Rhodes AR, Dennehy PH: Disseminated intravascular coagulation and purpura fulminans in a patient with Candida sepsis. Biopsy of purpura fulminans as an aid to diagnosis of systemic Candida infection. Am J Med 80:679–684, 1986.

    Article  CAS  PubMed  Google Scholar 

  74. Castaldo P, Stratta RJ, Wood RP, et al: Clinical spectrum of fungal infections after orthotopic liver transplant. Arch Surg 126:149–156, 1991.

    CAS  PubMed  Google Scholar 

  75. Thaler M, Pastakia B, Shawker TH, et al: Hepatic candidiasis in cancer patients: The evolving picture of the syndrome. Ann Intern Med 108:88–100, 1988.

    CAS  PubMed  Google Scholar 

  76. Pestalozzi BC, Krestin GP, Schanz U, et al: Hepatic lesions of chronic desseminated candidiasis may become invisible during neutropenia. Blood 90:3858–3864, 1997.

    CAS  PubMed  Google Scholar 

  77. Karp JE, Merz WG, Charache P: Response to empiric amphotericin B during antileukemic therapy-induced granulocytopenia. Rev Infect Dis 13:592–599, 1991.

    CAS  PubMed  Google Scholar 

  78. Walsh TJ, Chanock SJ: Laboratory diagnosis of invasive candidiasis: A rationale for complementary use of culture-and nonculture-based detection systems. Int J Infect Dis 1(Suppl 1): S11–S19, 1997.

    Google Scholar 

  79. Christensson B, Wiebe T, Pehrson C, Larsson L: Diagnosis of invasive candidiasis in neutropenic children with cancer by determination of D-arabinitol/L-arabinitol ratios in urine. J Clin Microbiol 35:636–640, 1997.

    CAS  PubMed  Google Scholar 

  80. Phillips P, Dowd A, Jewesson P, et al: Nonvalue of antigen detection immunoassays for diagnosis of candidemia. J Clin Microbiol 28:2320–2326, 1990.

    CAS  PubMed  Google Scholar 

  81. Morhart M, Rennie R, Ziola B, et al: Evaluation of enzyme immunoassay for Candida cytoplasmic antigens in neutropenic cancer patients. J Clin Microbiol 32:766–776, 1994.

    CAS  PubMed  Google Scholar 

  82. Hossain MA, Miyazaki T, Mitsutake K, et al: Comparison between Wako-WB003 and Fungitec G tests for detection of (I→3)-β-D-glucan in systemic mycosis. J Clin Lab Anal 11:73–77, 1997.

    Article  CAS  PubMed  Google Scholar 

  83. Einsele H, Hebart H, Roller G, et al: Detection and identification of fungal pathogens in blood by using molecular probes. J Clin Microbiol 35:1353–1360, 1997.

    CAS  PubMed  Google Scholar 

  84. Martinez JP, Gil ML, López-Ribot JL, Chaffin WL: Serologic response to cell wall mannoproteins and proteins of Candida albicans. Clin Microbiol Rev 11:121–141, 1998.

    CAS  PubMed  Google Scholar 

  85. Preisler HD, Hasenclever HF, Henderson ES: Anti-Candida antibodies in patients with acute leukemia: A prospective study. Am J Med 51:352–361, 1971.

    Article  CAS  PubMed  Google Scholar 

  86. Wingard JR: Infections due to resistant Candida species in patients with cancer who are receiving chemotherapy. Clin Infect Dis 19 (Suppl 1):S49–S53, 1994.

    PubMed  Google Scholar 

  87. Rex J: Editorial response: Catheters and candidemia. Clin Infect Dis 22:467–470, 1996.

    CAS  PubMed  Google Scholar 

  88. Edwards JE Jr, Bodey GP, Bowden RA, et al: International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis 25: 43–59, 1997.

    PubMed  Google Scholar 

  89. Powderly W, Kobayashi G, Herzig GP: Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med 4:826–832, 1988.

    Google Scholar 

  90. Ringdén O, Meunier F, Tollemar J, et al: Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 28(Suppl B):73–82, 1991.

    PubMed  Google Scholar 

  91. Noskin GA, Pietrelli L, Coffey G, et al: Amphotericin B colloidal dispersion for treatment of candidemia in immunocompromised patients. Clin Infect Dis 26:461–467, 1998.

    CAS  PubMed  Google Scholar 

  92. Walsh TJ, Hiemenz JW, Seibel NL, et al: Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases. Clin Infect Dis 26:1383–1396, 1998.

    CAS  PubMed  Google Scholar 

  93. Wingard JR: Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses. Bone Marrow Transplant 19:343–347, 1997.

    Article  CAS  PubMed  Google Scholar 

  94. Merhav H, Mieles L: Amphotericin B lipid complex in the treatment of invasive fungal infections in liver transplant patients. Transplant Proc 29:2670–2674, 1997.

    Article  CAS  PubMed  Google Scholar 

  95. Anaissie EJ, White MH, Uzun O, et al: Amphotericin B lipid complex vs. amphotericin B for treatment of invasive candidiasis: A prospective, randomized multicenter trial. Abst #LM21. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1995, p. 330.

    Google Scholar 

  96. Horn R, Wong B, Kiehn TE, Armstrong D: Fungemia in a cancer hospital: Changing frequency, earlier on set, and results of therapy. Rev Infect Dis 7:646–655, 1985.

    CAS  PubMed  Google Scholar 

  97. Kauffman CA, Bradley SF, Ross SC, Weber DR: Hepatosplenic candidiasis: Successful treatment with fluconazole. Am J Med 91:137–141, 1991.

    Article  CAS  PubMed  Google Scholar 

  98. Anaissie E, Bodey GP, Kantarjian H, et al: Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med 91:142–150, 1991.

    Article  CAS  PubMed  Google Scholar 

  99. Poynton CH, Barnes RA, Rees J: Interferon γ and granulocyte-macrophage colony-stimulating factor for the treatment of hepato-splenic candidosis in patients with acute leukemia. Clin Infect Dis 26:239–240, 1998.

    CAS  PubMed  Google Scholar 

  100. Capetti A, Bonfanti P, Magni C, Milazzo F: Employment of recombinant human granulocyte-macrophage colony stimulating factor in oesophageal candidiasis in AIDS patients. AIDS 9:1378, 1995.

    CAS  PubMed  Google Scholar 

  101. Vazquez JA, Gupta S, Villanueva A: Potential utility of recombinant human GM-CSF as adjunctive treatment of refractory oropharyngeal candidiasis in AIDS patients. Eur J Clin Microbiol Infect Dis 17:781–783, 1998.

    Article  CAS  PubMed  Google Scholar 

  102. Bjerke JW, Meyers JD, Bowden RA: Hepatosplenic candidiasis—A contraindication to marrow transplantation. Blood 84:2811–2814, 1994.

    CAS  PubMed  Google Scholar 

  103. Rex JH, Walsh TJ, Sobel JD, et al: Practice guidelines for the treatment of candidiasis. Clin Infect Dis 30:662–678, 2000.

    Article  CAS  PubMed  Google Scholar 

  104. Ribaud P, Chastang C, Latgé JP, et al: Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis 28:322–330, 1999.

    CAS  PubMed  Google Scholar 

  105. Leenders A, Van Belkum A, Janssen S, et al: Molecular epidemiology of apparent outbreak of invasive aspergillosis in a hematology ward. J Clin Microbiol 34:345–351, 1996.

    CAS  PubMed  Google Scholar 

  106. Hospenthal D, Kwon-Chung KJ, Bennett JE: Concentrations of airborne Aspergillus compared to the incidence of invasive aspergillosis: Lack of correlation. Med Mycol 36:165–168, 1998.

    Article  CAS  PubMed  Google Scholar 

  107. Hamadeh R, Ardehali A, Locksley RM, York MK: Fatal aspergillosis associated with smoking contaminated marijuana, in a marrow transplant recipient. Chest 94:432–433, 1984.

    Google Scholar 

  108. Karp E, Burch PA, Merz WG: An approach to intensive antileukemia therapy in patients with previous invasive aspergillosis. Am J Med 85:203–206, 1988.

    CAS  PubMed  Google Scholar 

  109. Armstrong D: Problems in management of opportunistic fungal diseases. Rev Infect Dis II:S1591–S1599, 1989.

    Google Scholar 

  110. Morrison VA, Haake RJ, Weisdorf DJ: Non-Candida fungal infections after bone marrow transplantation: Risk factors and outcome. Am J Med 96:497–503, 1994.

    Article  CAS  PubMed  Google Scholar 

  111. Meyers JD: Fungal infection in bone marrow transplant patients. Semin Oncol 3:10–13, 1990.

    Google Scholar 

  112. Paterson DL, Singh N: Invasive aspergillosis in transplant recipients. Medicine 78:123–138, 1999.

    Article  CAS  PubMed  Google Scholar 

  113. Singh N, Arnow PM, Bonham A, et al: Invasive aspergillosis in liver transplant recipients in the 1990s. Transplantation 64:716–720, 1997.

    CAS  PubMed  Google Scholar 

  114. Denning DW: Invasive aspergillosis. Clin Infect Dis 26:781–803, 1998.

    CAS  PubMed  Google Scholar 

  115. Clark A, Skeleton J, Fraser RS: Fungal tracheobronchitis report of 9 cases and review of the literature. Medicine 70:1–14, 1991.

    Google Scholar 

  116. Talbot GH, Huang A, Provencher M: Invasive aspergillus rhinosinusitis in patients with acute leukemia. Rev Infect Dis 13:219–232, 1991.

    CAS  PubMed  Google Scholar 

  117. Denning DW, Marinus A, Cohen J, et al: An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: Diagnosis and therapeutic outcome. J Infect 37:173–180, 1998.

    Article  CAS  PubMed  Google Scholar 

  118. Burch PA, Karp JE, Merz WG, et al: Favorable outcome of invasive aspergillosis in paitents with acute leukemia. J Clin Oncol 5:1985–1993, 1987.

    CAS  PubMed  Google Scholar 

  119. Reiss P, Hadderingh R, Schot LJ, Dannder SA: Invasive external otitis caused by Aspergillus fumigatus in two patients with AIDS. AIDS 5:605–606, 1991.

    CAS  PubMed  Google Scholar 

  120. Bodey GP, Vartivarian S: Aspergillosis. Eur J Clin Microbiol Infect Dis 8:413–437, 1989.

    CAS  PubMed  Google Scholar 

  121. Caillot D, Casasnovas O, Bernard A, et al: Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 15:139–147, 1997.

    CAS  PubMed  Google Scholar 

  122. Brown MJ, Worthy SA, Flint JD, Muller NL: Invasive aspergillosis in the immunocompromised host: Utility of computed tomography and bronchoalveolar lavage. Clin Radial 53:255–257, 1998.

    CAS  Google Scholar 

  123. Albelda SM, Talbot GH, Gerson SL, et al: Role of fiberoptic bronchoscopy in the diagnosis of invasive pulmonary aspergillosis in patients with acute leukemia. Am J Med 76:1027–1034, 1984.

    Article  CAS  PubMed  Google Scholar 

  124. Horvath J, Dummer S: The use of respiratory tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med 100:171–178, 1996.

    Article  CAS  PubMed  Google Scholar 

  125. Aisner J, Murillo J, Schimpff SC, Steere AC: Invasive aspergillosis in acute leukemia: Correlation with nose cultures and antibiotic use. Ann Intern Med 90:4–9, 1979.

    CAS  PubMed  Google Scholar 

  126. Nunley DR, Ohori NP, Grgurich WF, et al: Pulmonary aspergillosis in cystic fibrosis lung transplant recipients. Chest 114: 1321–1329, 1998.

    CAS  PubMed  Google Scholar 

  127. Verweij PE, Stynen D, Rijs AJMM, et al: Sandwich enzyme-linked immunosorbent assay compared with Pastorex latex agglutination test for diagnosing invasive aspergillosis in immunocompromised patients. J Clin Microbiol 33:1912–1914, 1995.

    CAS  PubMed  Google Scholar 

  128. Severens JL, Donnelly JP, Meis JFGM, et al: Two strategies for managing invasive aspergillosis: A decision analysis. Clin Infect Dis 25:1148–1154, 1997.

    CAS  PubMed  Google Scholar 

  129. Yuasa K, Goto H, Iguchi M, et al: Evaluation of the diagnostic value of the measurement of (1→3)-β-d-glucan in patients with pulmonary aspergillosis. Respiration 63:78–83, 1996.

    CAS  PubMed  Google Scholar 

  130. Kaiser L, Huguenin T, Lew PD, et al: Invasive aspergillosis—Clinical features of 35 proven cases at a single institution. Medicine 77:188–194, 1998.

    Article  CAS  PubMed  Google Scholar 

  131. Allo MD, Miller J, Townsend T, Cissy T: Primary cutaneous aspergillosis associated with Hickman intravenous catheters. N Engl J Med 317:1105–1108, 1987.

    CAS  PubMed  Google Scholar 

  132. Oppenheim BA, Herbrecht R, Kusne S: The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis 21:1145–1153, 1995.

    CAS  PubMed  Google Scholar 

  133. White A, Anaissie E, Kusne S, et al: Amphotericin B colloidal dispersion vs. amphotericin B-as therapy for invasive aspergillosis. Clin Infect Dis 24:635–642, 1997.

    CAS  PubMed  Google Scholar 

  134. Mills W, Chopra R, Linch DC, Goldstone AH: Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: A single-centre experience of 133 episodes in 116 patients. Br J Haematol 86:754–760, 1994.

    CAS  PubMed  Google Scholar 

  135. Ellis M, Spence D, De Pauw B, et al: An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 27:1406–1412, 1998.

    CAS  PubMed  Google Scholar 

  136. Denning DW, Tucker RM, Hanson LH, Stevens FA: Treatment of invasive aspergillosis with itraconazole. Am J Med 86:791–800, 1989.

    Article  CAS  PubMed  Google Scholar 

  137. Viviani MA, Tortorano AM, Pagano A, et at. European experience with itraconazole in systemic mycoses. J Am Acad Dermatol 9(Suppl 1):S77–S86, 1987.

    Google Scholar 

  138. Dupont B: Itraconazole therapy in aspergillosis: Study in 49 patients. J Am Acad Dermatol 23:607–614, 1990.

    CAS  PubMed  Google Scholar 

  139. Sánchez C, Mauri E, Dalmau D, et al: Treatment of cerebral aspergillosis with itraconazole: Do high doses improve the prognosis? Clin Infect Dis 21:1485–1487, 1995.

    PubMed  Google Scholar 

  140. Denning DW, Venkateswarlu K, Oakley KL, et al: Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 41:1364–1368, 1997.

    CAS  PubMed  Google Scholar 

  141. Chryssanthou E: In vitro susceptibility of respiratory isolates of Aspergillus species to itraconazole and amphotericin B. Acquired resistance to itraconazole. Scand J Infect Dis 29:509–512, 1997.

    CAS  PubMed  Google Scholar 

  142. Oakley KL, Moore CB, Denning DW: In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. Antimicrob Agents Chemother 41:1124–1126, 1997.

    CAS  PubMed  Google Scholar 

  143. Graybill JR, Bocanegra R, Najvar LK, et al: SCH56592 treatment of murine invasive aspergillosis. J Antimicrob Chemother 42: 539–542, 1998.

    Article  CAS  PubMed  Google Scholar 

  144. Petraitis V, Petraitiene R, Groll AH, et al: Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 42: 2898–2905, 1998.

    CAS  PubMed  Google Scholar 

  145. Jones TC: Use of granulocyte-macrophage colony stimulating factor (GM-CSF) in prevention and treatment of fungal infections. Eur J Cancer [A] 35:S8–S10, 1999.

    CAS  Google Scholar 

  146. Armitage J: Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. J Am Soc Hematol 92:4491–4508, 1998.

    CAS  Google Scholar 

  147. Viollier AF, Peterson DE, DeJongh CA, et al: Aspergillus sinusitis in cancer patients. Cancer 58:366–371, 1986.

    CAS  PubMed  Google Scholar 

  148. Reichenberger F, Habicht J, Kaim A, et al: Lung resection for invasive pulmonary aspergillosis in neutropenic patients with hematologic diseases. Am J Respir Crit Care Med 158:885–890, 1998.

    CAS  PubMed  Google Scholar 

  149. Stevens DA, Kan VL, Judson MA, et al: Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 30:696–709, 2000.

    Article  CAS  PubMed  Google Scholar 

  150. Opal SM, Asp AA, Canady PB Jr, et al: Efficacy of infection control measure during a nosocomial outbreak of disseminated aspergillosis associated with hospital construction. J Infect Dis 153:634–637, 1986.

    CAS  PubMed  Google Scholar 

  151. Meunier F: Prevention of mycoses in immunocompromised patients. Rev Infect Dis 9:408–416, 1987.

    CAS  PubMed  Google Scholar 

  152. Sherertz RJ, Belani A, Kramer BS, et al: Impact of air filtration on nosocomial Aspergillus infections unique risk of bone marrow transplant recipients. Am J Med 83:709–718, 1987.

    CAS  PubMed  Google Scholar 

  153. Conneally E, Cafferkey MT, Daly PA, et al: Nebulized amphotericin B as prophylaxis against invasive aspergillosis in granulocyto-penic patients. Bone Marrow Transplant 5:403–406, 1990.

    CAS  PubMed  Google Scholar 

  154. Bodey GP, Johnston D: Microbiological evaluation of protected environments during patient occupancy. Appl Microbiol 22:828–836, 1999.

    Google Scholar 

  155. Singh N, Gayowski T, Singh J, Yu VL: Invasive gastrointestinal zygomycosis in a liver transplant recipient: Case report and review of zygomycosis in solid-organ transplant recipients. Clin Infect Dis 20:617–620, 1995.

    CAS  PubMed  Google Scholar 

  156. Gaziev D, Baronciani D, Galimberti M, et al: Mucormycosis after bone marrow transplantation: Report of four cases in thalassemia and review of the literature. Bone Marrow Transplant 17:409–414, 1996.

    CAS  PubMed  Google Scholar 

  157. Morrison VA, McGlave PB: Mucormycosis in the BMT population. Bone Marrow Transplant 11:383–388, 1993.

    CAS  PubMed  Google Scholar 

  158. Blitzer A, Lawson W, Meyers BR, Biller HF: Patient survival factors in paranasal sinus zygomycosis. Laryngoscope 90:635–648, 1980.

    CAS  PubMed  Google Scholar 

  159. Lehrer RI, Howard DH, Sypherd PS, et al: Zygomycosis. Ann Intern Med 93:93–108, 1980.

    Google Scholar 

  160. Ferguson BJ, Mitchell TG, Moon R, et al: Adjunctive hyperbaric oxygen for treatment of rhinocerebral zygomycosis. Rev Infect Dis 10:551–559, 1988.

    CAS  PubMed  Google Scholar 

  161. Gonzalez CE, Couriel DR, Walsh TJ: Disseminated zygomycosis in a neutropenic patient: Successful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor. Clin Infect Dis 24:192–196, 1997.

    CAS  PubMed  Google Scholar 

  162. Groll AH, Walsh TJ: Potential new antifungal agents. Curr Opin Infect Dis 10:449–458, 1997.

    Google Scholar 

  163. Nelson PE, Dignani MC, Anaissie EJ: Taxonomy, biology, and clinical aspects of Fusarium species. Clin Microbiol Rev 7:479–504, 1994.

    CAS  PubMed  Google Scholar 

  164. Hennequin C, Lavarde V, Poirot JL, et al: Invasive Fusarium infections: A retrospective survey of 31 cases. J Med Vet Mycol 35:107–114, 1997.

    CAS  PubMed  Google Scholar 

  165. Lozano-Chiu M, Arikan S, Paetznick VL, et al: Treatment of murine fusariosis with SCH 56592. Antimicrob Agents Chemother 43:589–591, 1999.

    CAS  PubMed  Google Scholar 

  166. Schroter GPJ, Temple DR, Husberg BS, et al: Cryptococcosis after renal transplantation: Report of ten cases. Surgery 79:268–277, 1976.

    CAS  PubMed  Google Scholar 

  167. Watson AJ, Russell RP, Cabreja RF, Braverman WA: Cure of cryptococcal infection during continued immunosuppressive therapy. Q J Med 55:169–172, 1985.

    CAS  PubMed  Google Scholar 

  168. Aberg JA, Mundy LM, Powderly WG: Pulmonary Cryptococcosis in patients without HIV infection. Chest 115:734–740, 1999.

    Article  CAS  PubMed  Google Scholar 

  169. Andreula CF, Burdi N, Carella A: CNS cryptococcosis in AIDS: Spectrum of MR findings. J Comput Assist Tomogr 17:438–441, 1993.

    CAS  PubMed  Google Scholar 

  170. Powderly WG, Cloud GA, Dismukes WE, Saag MS: Measurement of cryptococcal antigen in serum and cerebrospinal fluid: Value in the management of AIDS-associated cryptococcal meningitis. Clin Infect Dis 18:789–792, 1994.

    CAS  PubMed  Google Scholar 

  171. Larsen RA, Bozzette S, McCutchan JA, et al: Persistent Cryptococcus neoformans infection of the prostate after successful treatment of meningitis. Ann Intern Med 111:125–128, 1989.

    CAS  PubMed  Google Scholar 

  172. Chan KH: Neurosurgical aspects of cerebral cryptococcosis. Neurosurgery 25:44–48, 1989.

    CAS  PubMed  Google Scholar 

  173. Gade W, Hinnefeld SW, Babcock LS, et al: Comparison of the premier cryptococcal antigen enzyme immunoassay and the latex agglutination assay for detection of cryptococcal antigens. J Clin Microbiol 29:1616–1619, 1991.

    CAS  PubMed  Google Scholar 

  174. Bennett JE, Dismukes WE, Duma RJ, et al: A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 301:126–131, 1979.

    CAS  PubMed  Google Scholar 

  175. Van der Horst CM, Saag MS, Cloud GA, et al: Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med 337:15–21, 1997.

    PubMed  Google Scholar 

  176. Saag MS, Powderly WG, Cloud GA, et al: Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 326:83–89, 1992.

    CAS  PubMed  Google Scholar 

  177. Groll A, Giri N, Petraitis V, et al: Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infections of the central nervous system. J Infect Dis 182:274–282, 2000.

    Article  CAS  PubMed  Google Scholar 

  178. Leenders A, Reiss P, Portegies P, et al: Lipsomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 11:1463–1471, 1997.

    CAS  PubMed  Google Scholar 

  179. DeGans J, Portegies P, Tiessens G, et al: Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitis. AIDS 6:185–190, 1990.

    Google Scholar 

  180. Armengou A, Porcar C, Mascaró J, García-Bragado F: Possible development of resistance to fluconazole during suppressive therapy for AIDS-associated cryptococcal meningitis. Clin Infect Dis 23:1337–1338, 1996.

    CAS  PubMed  Google Scholar 

  181. Witt MD, Lewis RJ, Edwards JE Jr, Ghannoum MA: Possible development of resistance to fluconazole during suppressive therapy for AIDS-associated cryptococcal meningitis—Reply. Clin Infect Dis 23:1338, 1996.

    Google Scholar 

  182. Paugam A, Dupouy-Camet J, Blanche P, et al: Increased fluconazole resistance of Cryptococcus neoformans isolated from a patient with AIDS and recurrent meningitis. Clin Infect Dis 19:975–976, 1994.

    CAS  PubMed  Google Scholar 

  183. Coker RJ, Harris JR: Failure of fluconazole treatment in cryptococcal meningitis despite adequate CSF levels. J Infect 23:101–103, 1991.

    Article  CAS  PubMed  Google Scholar 

  184. Larsen RA, Bozzette SA, Jones BE, et al: Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 19:741–745, 1994.

    CAS  PubMed  Google Scholar 

  185. Bozzette SA, Larsen RA, Chiu J, et al: A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. N Engl J Med 324:580–584, 1991.

    CAS  PubMed  Google Scholar 

  186. Powderly WG, Saag MS, Cloud GA, et al: A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 326:793–798, 1992.

    CAS  PubMed  Google Scholar 

  187. Saag MS, Cloud GA, Graybill JR, et al: A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. Clin Infect Dis 28:291–296, 1999.

    CAS  PubMed  Google Scholar 

  188. Saag MS, Graybill RJ, Larsen RA, et al: Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 30:710–718, 2000.

    Article  CAS  PubMed  Google Scholar 

  189. Jahangir M, Hussain I, Ul H, Haroon TS: A double-blind, randomized, comparative trial of itraconazole versus terbinafine for 2 weeks in tinea capitis. Br J Dermatol 139:672–674, 1998.

    Article  CAS  PubMed  Google Scholar 

  190. Brummer E, Stevens DA: Macrophage colony-stimulating factor induction of enhanced macrophage anticryptococcal activity: Synergy with fluconazole for killing. J Infect Dis 170:173–179, 1994.

    CAS  PubMed  Google Scholar 

  191. Bach MC, Adler JL, Breman J, et al: Influence of rejection therapy on fungal and nocardia infections in renal-transplant recipients. Lancet 1:180–184, 1973.

    CAS  PubMed  Google Scholar 

  192. Watson AJ, Whelton A, Russell RP: Cure of cryptococcemia and preservation of graft function in a renal transplant recipient. Arch Intern Med 144:1877–1878, 1984.

    Article  CAS  PubMed  Google Scholar 

  193. Kong NCT, Shaariah W, Morad Z, et al: Cryptococcosis in a renal unit. Aust NZ J Med 20:645–649, 1990.

    CAS  Google Scholar 

  194. Graybill JR, Sobel J, Saag M, et al: Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. Clin Infect Dis 30:47–54, 2000.

    Article  CAS  PubMed  Google Scholar 

  195. Powderly WG, Finkelstein DM, Feinberg J, et al: A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med 332:700–705, 1995.

    Article  CAS  PubMed  Google Scholar 

  196. McKinsey DS, Wheat LJ, Cloud GA, et al: Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: Randomized, placebo-controlled, double-blind study. Clin Infect Dis 28:1049–1056, 1999.

    CAS  PubMed  Google Scholar 

  197. Iitaka K, McEnery PT, West CD: Successful renal transplantation after generalized cryptococcosis. J Pediatr 92:422–423, 1978.

    CAS  PubMed  Google Scholar 

  198. Mills SA, Seigler HF, Wolfe WG: The incidence and management of pulmonary mycosis in renal allograft patients. Ann Surg 182: 617–626, 1975.

    CAS  PubMed  Google Scholar 

  199. Wheat L: Histoplasmosis in the acquired immunodeficiency syndrome. Curr Top Med Mycol 7:7–18, 1996.

    CAS  PubMed  Google Scholar 

  200. Wheat LJ, Smith EJ, Sathapatayavongs B, et al: Histoplasmosis in renal allograft recipients: Two large urban outbreaks. Arch Intern Med 143:703–707, 1983.

    Article  CAS  PubMed  Google Scholar 

  201. Hughes WT: Hematogenous histoplasmosis in the immunocompromised child. J. Pediatr 105:569–575, 1984.

    CAS  PubMed  Google Scholar 

  202. Vail G, Young R, Filo RS, et al: Incidence of histoplasmosis following allogeneic bone marrow transplant (aBMT) or solid organ transplant (SOT) in a hyperendemic area. Abst # 3465a. In Program and Abstracts of the 36th Infectious Diseases Society of America Meeting, Denver, CO, 1998, p. 141.

    Google Scholar 

  203. Hood AB, Inglis FG, Lowenstein L, et al: Histoplasmosis and thrombocytopenic purpura: Transmisson by renal homotransplantation. Can Med Assoc J 93:587–592, 1965.

    CAS  PubMed  Google Scholar 

  204. Wheat J: Histoplasmosis: Experience during outbreaks in Indianapolis and review of the literature. Medicine 76:339–354, 1997.

    Article  CAS  PubMed  Google Scholar 

  205. Sridhar NR, Tchervenkov JI, Weiss MA, et al: Disseminated histoplasmosis in a renal transplant patient: A cause of renal failure several years following transplantation. Am J Kidney Dis 17:719–721, 1991.

    CAS  PubMed  Google Scholar 

  206. Wheat LJ, Kohler RB, Tewari RP: Diagnosis of disseminated histoplasmosis by detection of Histoplasma capsulatum antigen in serum and urine specimens. N Engl J Med 314:83–88, 1986.

    CAS  PubMed  Google Scholar 

  207. Sathapatayavongs B, Batteiger BE, Wheat LJ, et al: Clinical and laboratory features of disseminated histoplasmosis during two large urban outbreaks. Medicine 62:263–270, 1983.

    CAS  PubMed  Google Scholar 

  208. Wheat LJ, Connolly-Stringfield PA, Baker RL, et al: Disseminated histoplasmosis in the acquired immune deficiency syndrome: Clinical findings, diagnosis and treatment, and review of the literature. Medicine 69:361–374, 1990.

    CAS  PubMed  Google Scholar 

  209. Johnson P, Wheat LJ, Cloud G, et al: A multicenter randomized trial comparing amphotericin B (AmB) and liposomal amphotericin B (AmBisome, LAmB) as induction therapy of disseminated histoplasmosis (DH) in AIDS patients. Ann Intern Med, in press, 2002.

    Google Scholar 

  210. Wheat J, Hafner R, Korzun AH, et al: Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. Am J Med 98:336–342, 1995.

    Article  CAS  PubMed  Google Scholar 

  211. Vullo V, Mastroianni CM, Ferone U, et al: Central nervous system involvement as a relapse of disseminated histoplasmosis in an Italian AIDS patient. J Infect 35:83–84, 1997.

    Article  CAS  PubMed  Google Scholar 

  212. Wheat J, MaWhinney S, Hafner R, et al: Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. Am J Med 103:223–232, 1997.

    CAS  PubMed  Google Scholar 

  213. Wheat J, Marichal P, Vanden Bossche H, et al: Hypothesis on the mechanism of resistance to fluconazole in Histoplasma capsulatum. Antimicrob Agents Chemother 41:410–414, 1997.

    CAS  PubMed  Google Scholar 

  214. Connolly P, Wheat J, Schnizlein-Bick C, et al: Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice. Antimicrob Agents Chemotherapy 43:322–328, 1999.

    CAS  Google Scholar 

  215. McKinsey DS, Gupta MR, Riddler SA, et al: Long-term amphotericin B therapy for disseminated histoplasmosis in patients with the acquired immune deficiency syndrome. Ann Intern Med 111: 655–659, 1989.

    CAS  PubMed  Google Scholar 

  216. Wheat J, Hafner R, Wulfson M, et al. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 118:610–616, 1993.

    CAS  PubMed  Google Scholar 

  217. Hecht FM, Wheat J, Korzun AH, et al: Itraconazole maintenance treatment for histoplasmosis in AIDS: A prospective, multicenter trial. J Acquir Immun Defic Syndr Hum Retrovirol 16:100–107, 1997.

    CAS  Google Scholar 

  218. Wheat J, Sarosi G, McKinsey D, et al: Practice guidelines for the management of patients with histoplasmosis. Clin Infect Dis 30: 688–695, 2000.

    CAS  PubMed  Google Scholar 

  219. Goldman M, Cloud GA, Smedema M, et al: Does long-term itraconazole prophylaxis result in in vitro azole resistance in mucosal Candida albicans isolates from persons with advanced human immunodeficiency virus infection? Antimicrob Agents Chemother 44:1585–1587, 2000.

    Article  CAS  PubMed  Google Scholar 

  220. Ampel NM, Ryan KJ, Carry PJ, et al: Fungemia due to Coccidioides immitis. Medicine 65:312–321, 1999.

    Google Scholar 

  221. Galgiani JN, Ampel NM: Coccidioidomycosis in human immunodeficiency virus-infected patients. J Infect Dis 162:1165–1169. 1990.

    CAS  PubMed  Google Scholar 

  222. Drutz D, Catanzaro A: Coccidioidomycosis Parts 1 and 2. Am Rev Respir Dis 117:559–585, 727–771, 1978.

    CAS  PubMed  Google Scholar 

  223. Singh VR, Smith DK, Lawrence J, et al: Coccidioidomycosis in patients infected with human immunodeficiency virus: Review of 91 cases at a single institution. Clin Infect Dis 23:563–568, 1996.

    CAS  PubMed  Google Scholar 

  224. Galgiani JN: Coccidioidomycosis in the immunosuppressed host. In Einstein HE, Catanzaro A (eds): Proceedings of the 5th International Conference on Coccidioidomycosis, National Foundation for Infectious Diseases, Washington, DC, 1996, pp. 312–318.

    Google Scholar 

  225. Pappagianis D, Zimmer BL: Serology of coccidioidomycosis. Clin Microbiol Rev 3:247–268, 1990.

    CAS  PubMed  Google Scholar 

  226. Smith CE, Saito MT, Beard RR, et al: Serological tests in the diagnosis and prognosis of coccidioidomycosis. Am J Hyg 52: 1–21, 1950.

    CAS  PubMed  Google Scholar 

  227. Fish DG, Ampel NM, Galgiani JN, et al: Coccidioidomycosis during human immunodeficiency virus infection: A review of 77 patients. Medicine 69:384–391, 1980.

    Google Scholar 

  228. Stevens D: Coccidioidomycosis. N Engl J Med 332:1077–1082, 1995.

    Article  CAS  PubMed  Google Scholar 

  229. Labadie ELMD, Hamilton RHMD: Survival improvement in coccidioidal meningitis by high-dose intrathecal amphotericin B. Arch Intern Med 146:2013–2018, 1985.

    Google Scholar 

  230. Galgiani JN, Catanzaro A, Cloud GA, et al: Fluconazole therapy for coccidioidal meningitis. Ann Intern Med 119:28–35, 1993.

    CAS  PubMed  Google Scholar 

  231. Galgiani J, Stevens D, Graybill J, Cloud G: Ketoconazole therapy of progressive coccidioidomycosis. Am J Med 84:603–610, 1988.

    Article  CAS  PubMed  Google Scholar 

  232. Catanzaro A, Galgiani JN, Levine BE, el al: Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis. Am J Med 98:249–256, 1995.

    Article  CAS  PubMed  Google Scholar 

  233. Classen DC, Burke JP, Smith CB: Treatment of coccidioidal meningitis with fluconazole. J Infect Dis 158:903–904, 1988.

    CAS  PubMed  Google Scholar 

  234. Galgiani JN, Catanzaro A, Cloud GA, et al: Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis: A randomized, double-blind trial. Ann Intern Med 133:676–686, 2000.

    CAS  PubMed  Google Scholar 

  235. Dewsnup DH, Galgiani JN, Graybill JR, et al: Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann Intern Med 124:305–310, 1996.

    CAS  PubMed  Google Scholar 

  236. Galgiani JN, Ampel NM, Catanzaro A, et al: Practice guidelines for the treatment of coccidioidomycosis. Clin Infect Dis 30:658–661, 2000.

    Article  CAS  PubMed  Google Scholar 

  237. Schroter GPJ, Bakshandeh K, Husberg BS, Weil R III: Coccidioidomycosis and renal transplantation. Transplantation 23:485–489, 1977.

    CAS  PubMed  Google Scholar 

  238. Pappas PG, Threlkeld MG, Bedsole GD, et al: Blastomycosis in immunocompromised patients. Medicine 72:311–325, 1993.

    CAS  PubMed  Google Scholar 

  239. Pappas PG, Pottage JC, Powderly WG, et al: Blastomycosis in patients with the acquired immunodeficiency syndrome. Ann Intern Med 116:847–853, 1992.

    CAS  PubMed  Google Scholar 

  240. Recht LD, Davies SF, Eckman MR, Sarosi GA: Blastomycosis in immunosuppressed patients. Am Rev Respir Dis 125:359–362, 1982.

    CAS  PubMed  Google Scholar 

  241. Laine L, Dretler RH, Conteas CN, et al: Fluconazole compared with ketoconazole for treatment of Candida esophagitis in AIDS. Ann Intern Med 117:655–660, 1992.

    CAS  PubMed  Google Scholar 

  242. Sarosi GA, Davies SF: Blastomycosis. Am Rev Respir Dis 120: 911–937, 1979.

    CAS  PubMed  Google Scholar 

  243. Wheat J, Wheat H, Connolly P, et al: Cross-reactivity in Histoplasma capsulaium variety capsulatum antigen assays of urine samples from patients with endemic mycoses. Clin Infect Dis 24: 1169–1171, 1997.

    CAS  PubMed  Google Scholar 

  244. Chapman SW, Bradsher RW Jr, Campbell GD Jr, et al: Practice guidelines for the management of patients with blastomycosis. Clin Infect Dis 30:679–683, 2000.

    Article  CAS  PubMed  Google Scholar 

  245. Gonyea EF: The spectrum of primary blastomycotic meningitis: A review of central nervous system blastomycosis. Ann Neurol 3: 26–39, 1978.

    Article  CAS  PubMed  Google Scholar 

  246. Dismukes WE, Bradsher RW Jr, Cloud GC, et al: Itraconazole therapy for blastomycosis and histoplasmosis. Am J Med 93:489–497, 1992.

    Article  CAS  PubMed  Google Scholar 

  247. Dismukes WE, Cloud G, Bowles C, et al: Treatment of blastomycosis and histoplasmosis with ketoconazole: Results of a prospective randomized clinical trial. Ann Intern Med 103:861–872, 1985.

    Google Scholar 

  248. Pappas PG, Bradsher RW, Kauffman CA, et al: Treatment of blastomycosis with higher doses of fluconazole. Clin Infect Dis 25:200–205, 1997.

    CAS  PubMed  Google Scholar 

  249. Vartivarian SE, Anaissie EJ, Bodey GP: Emerging fungal pathogens in immunocompromised patients: Classification, diagnosis, and management. Clin Infect Dis 17(Suppl 2):S487–S491, 1993.

    PubMed  Google Scholar 

  250. Walsh TJ, Groll AH: Emerging fungal pathogens: Evolving challenges to immunocompromised patients for the twenty-first century. Transplant Infect Dis 1:247–261, 1999.

    Article  CAS  Google Scholar 

  251. Anaissie E, Bodey GP, Rinaldi MG: Emerging fungal pathogens. Eur J Clin Microbiol Infect Dis 8:323–330, 1989.

    Article  CAS  PubMed  Google Scholar 

  252. Supparatpinyo K, Khamwan C, Baosoung V, et al: Disseminated Penicillium marneffei infection in Southeast Asia. Lancet 334: 110–113, 1994.

    Google Scholar 

  253. Goldani LZ, Sugar AM: Paracoccidioidomycosis and AIDS: An overview. Clin Infect Dis 21:1275–1281, 1995.

    CAS  PubMed  Google Scholar 

  254. Walsh TJ, Peter J, McGough DA, et al: Activities of amphotericin B and antifungal azoles alone and in combination against Pseud-allescheria boydii. Antimicrob Agents Chemother 39:1361–1364, 1995.

    CAS  PubMed  Google Scholar 

  255. Patterson TF, Andriole VT, Zervos MJ, et al: The epidemiolog y of pseudallescheriasis complicating transplantation: Nosocomial and community-acquired infection. Mycoses 33:297–302, 1990.

    CAS  PubMed  Google Scholar 

  256. Goldberg SL, Geha DJ, Marshall WF, et al: Successful treatment of simultaneous pulmonary Pseudallescheria boydii and Aspergillus terreus infection with oral itraconazole. Clin Infect Dis 16:803–805, 1993.

    CAS  PubMed  Google Scholar 

  257. Ruxin TA, Steck WD, Helm TN, et al: Pseudallescheria boydii in an immunocompromised host—Successful treatment with debridement and itraconazole. Arch Dermatol 132:382–384, 1996.

    Article  CAS  PubMed  Google Scholar 

  258. Verweij PE, Cox NJM, Meis JFG: Oral terbinafine for treatment of pulmonary Pseudallescheria boydii infection refractory to itraconazole therapy. Eur J Clin Microbiol Infect Dis 16:26–28, 1997.

    Article  CAS  PubMed  Google Scholar 

  259. Sharkey PK, Graybill JR, Rinaldi MG, et al: Itraconazole treatment of phaeohyphomycosis. J Am Acad Dermatol 23:577–586, 1990.

    CAS  PubMed  Google Scholar 

  260. Anaissie E, Bodey GP, Kantarjian H, et al: New spectrum of fungal infection in patients with cancer. Rev Infect Dis 11:369–378, 1989.

    CAS  PubMed  Google Scholar 

  261. Lowenthal RM, Atkinson K, Challis DR, et al: Invasive Trichosporon cutaneum infection: An increasing problem in immunosuppressed patients. Bone Marrow Transplant 2:321–327, 1987.

    CAS  PubMed  Google Scholar 

  262. Gallis HA, Drew RH, Pickard WW: Amphotericin B: 30 years of clinical experience. Rev Infect Dis 12:308–329, 1987.

    Google Scholar 

  263. Walsh TJ, Pizzo A: Treatment of systemic fungal infections: Recent progress and current problems. Eur J Clin Microbiol Infect Dis 7:460–475, 1988.

    Article  CAS  PubMed  Google Scholar 

  264. Wong-Beringer A, Jacobs RA, Guglielmo BJ: Lipid formulations of amphotericin B: Clinical efficacy and toxicities. Clin Infect Dis 27:603–618, 1998.

    CAS  PubMed  Google Scholar 

  265. Walsh TJ, Finberg RW, Arndt C, et al: Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 340:764–771, 1999.

    Article  CAS  PubMed  Google Scholar 

  266. Dix SP: Pharmacology of lipid formulations of amphotericin B. Infect Dis Clin Pract 7:S8–S15, 1998.

    Google Scholar 

  267. Storm G, Van Etten E: Biopharmaceutical aspects of lipid formulations of amphotericin B. Eur J Clin Microbiol Infect Dis 16:64–73, 1997.

    Article  CAS  PubMed  Google Scholar 

  268. Petersen D, Demertzis S, Freund M, et al: Individualization of 5-fluorocytosine therapy. Chemotherapy 40:149–156, 1994.

    CAS  PubMed  Google Scholar 

  269. Stamm AM, Diasio RB, Dismukes WE, et al: Toxicitiy of amphotericin B plus flucytosine in 194 patients with cryptococcal meningtitis. Am J Med 83:236–242, 1987.

    Article  CAS  PubMed  Google Scholar 

  270. Kitchen VS, Savage M, Harris JRW: Candida albicans resistance in AIDS [letter to the editor]. J Infect 22:204–205, 1991.

    Article  CAS  PubMed  Google Scholar 

  271. Fox R, Neal KR, Leen CLS, et al: Fluconazole resistant Candida in AIDS. J Infect 22:201–212, 1991.

    Article  CAS  PubMed  Google Scholar 

  272. Brammer KW, Farrow PR, Faulkner JK: Clinical pharmacology pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis 12:S318–S326, 1990.

    PubMed  Google Scholar 

  273. Apseloff G, Hilligoss DM, Gardner MJ, et al: Induction of fluconazole metabolism by rifampin: In vivo study in humans. J Clin Pharmacol 31:358–361, 1991.

    CAS  PubMed  Google Scholar 

  274. Blum RA, Wilton JH, Hilligoss DM, et al: Effect of fluconazole on the disposition of phenytoin. Clin Pharmacol Ther 49:420–425, 1991.

    CAS  PubMed  Google Scholar 

  275. Canafax DM, Graves NM, Hilligoss DM, et al: Increased cyclosporine levels as a result of simultaneous fluconazole and cyclosporine therapy in renal transplant recipients: A double-blind, randomized pharmacokinetic and safety study. Transplant Proc 23:1041–1042, 1991.

    CAS  PubMed  Google Scholar 

  276. Graybill JR, Stevens DA, Galgiani N, et al: Itraconazole treatment of coccidioidomycosis. Am J Med 89:282–290, 1990.

    Article  CAS  PubMed  Google Scholar 

  277. Stevens DA: Itraconazole and fluconazole for treatment of coccidioidomycosis. Clin infect Dis 18:470–470, 1994.

    CAS  PubMed  Google Scholar 

  278. Tucker RM, Denning DW, Arathoon EG, et al: Itraconazole therapy for nonmeningeal coccidioidomyosis: Clinical and laboratory observation. J Am Acad Dermatol 23:593–601, 1990.

    CAS  PubMed  Google Scholar 

  279. Tucker RM, Haq Y, Denning DW, Stevens DA: Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother 26:561–566, 1990.

    CAS  PubMed  Google Scholar 

  280. Diaz M, Puente R, DeHoyos LA, Cruz S: Itraconazole in the treatment of coccidioidomycosis. Chest 100:682–684, 1990.

    Google Scholar 

  281. Sharkey-Mathis PK, Kauffman CA, Graybill JR, et al: Treatment of sporotrichosis with itraconazole. Am J Med 95:279–285, 1993.

    CAS  PubMed  Google Scholar 

  282. Grant SM, Clissold SP: Itraconazole A: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 37:310–344, 1989.

    CAS  PubMed  Google Scholar 

  283. Van’t Wout JW, Novakova I, et al: The efficacy of itraconazole against systemic fungal infections in neutropenic patients: A randomized comparative study with amphotericin B. J Infect 22:45–52, 1991.

    Google Scholar 

  284. Barchiesi F, Colombo AL, McGough DA, et al: In vitro activity of itraconazole against fluconazole-susceptible and-resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 38:1530–1533, 1994.

    CAS  PubMed  Google Scholar 

  285. Phillips P, Zemcov J, Mahmood W, et al: Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: Correlation of clinical response with in vitro susceptibility. AIDS 10:1369–1376, 1996.

    CAS  PubMed  Google Scholar 

  286. Cartledge JD, Midgley J, Gazzard BG: Itraconazole cyclodextrin solution: The role of in vitro susceptibility testing in predicting successful treatment of HIV-related fluconazole-resistant and fluconazole-susceptible oral candidosis. AIDS 11:163–168, 1997.

    Article  CAS  PubMed  Google Scholar 

  287. Blomley M, DeBelder A, Thyway Y, Weston M: Itraconazole and anti-tuberculosis drugs. Lancet 336:1255, 1991.

    Google Scholar 

  288. Kramer MR, Marshall SE, Denning DW, et al: Cyclosporine and itraconazole interaction in heart and lung transplant recipients. Ann Intern Med 113:327–329, 1990.

    CAS  PubMed  Google Scholar 

  289. Sharkey PK, Rinaldi MG, Dunn JF, et al: High-dose itraconazole in the treatment of severe mycoses. Antimicrob Agents Chemother 35:707–713, 1991.

    CAS  PubMed  Google Scholar 

  290. Tucker RM, Denning DW, Dupont B, Stevens DA: Itraconazole therapy for chronic coccidioidal meningitis. Ann Intern Med 112:108–112, 1990.

    CAS  PubMed  Google Scholar 

  291. Belanger P, Nast CC, Fratti R, et al: Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and-resistant Candida species. Antimicrob Agents Chemother 41:1840–1842, 1997.

    CAS  PubMed  Google Scholar 

  292. Hegener P, Troke PF, Fätkenheuer G, et al: Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS. AIDS 12:2227–2228, 1998.

    CAS  PubMed  Google Scholar 

  293. Pfaller MA, Zhang J, Messer SA, et al: In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob Agents Chemother 43:169–171, 1999.

    CAS  PubMed  Google Scholar 

  294. Cuenca-Estrella M, Rodríguez-Tudela JL, Mellado E, et al: Comparison of the in vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. J Antimicrob Chemother 42:531–533, 1998.

    Article  CAS  PubMed  Google Scholar 

  295. Murphy M, Bernard EM, Ishimaru T, Armstrong D: Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 41:696–698, 1997.

    CAS  PubMed  Google Scholar 

  296. Van’t Hek LG, Verweij PE, Weemaes CM, et al: Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease. Am J Respir Crit Care Med 157:1694–1696, 1998.

    Google Scholar 

  297. Schwartz S, Milatovic D, Thiel E: Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia. Br J Haematol 97:663–665, 1997.

    Article  CAS  PubMed  Google Scholar 

  298. Girmenia C, Luzi G, Monaco M, Martino P: Use of voriconazole in treatment of Scedosporium apiospermum infection: Case report. J Clin Microbiol 36:1436–1438, 1998.

    CAS  PubMed  Google Scholar 

  299. Johnson EM, Szekely A, Warnock DW: In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother 42:741–745, 1998.

    CAS  PubMed  Google Scholar 

  300. Radford SA, Johnson EM, Warnock DW: In vitro studies of activity of voriconazole (WK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrob Agents Chemother 41:841–843, 1997.

    CAS  PubMed  Google Scholar 

  301. Lutz JE, Clemons KV, Aristizabal BH, Stevens DA: Activity of the triazole SCH 56592 against disseminated murine coccidioido-mycohsis. Antimicrob Agents Chemother 41:1558–1561, 1997.

    CAS  PubMed  Google Scholar 

  302. Law D, Moore CB, Denning DW: Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp. Antimicrob Agents Chemother 41:2310–2311, 1997.

    CAS  PubMed  Google Scholar 

  303. Bartizal K, Gill CJ, Abruzzo GK, et al: In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother 41:2326–2332, 1997.

    CAS  PubMed  Google Scholar 

  304. Graybill JR, Bocanegra R, Luther M, et al: Treatment of murine Candida krusei or Candida glabrata infection with L-743,872. Antimicrob Agents Chemother 41:1937–1939, 1997.

    CAS  PubMed  Google Scholar 

  305. Bartlett MS, Current WL, Goheen MP, et al: Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo. Antimicrob Agents Chemother 40:1811–1816, 1996.

    CAS  PubMed  Google Scholar 

  306. Boswell GW, Buell D, Bekersky I: AmBisome (liposomal amphotericin B): A comparative review. J Clin Pharmacol 38:583–592, 1998.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Medicine and Pathology, Indiana University School of Medicine, Indianapolis, Indiana, 46202

    L. Joseph Wheat

  2. Department of Veterans Affairs Hospital, Indianapolis, Indiana, 46202

    L. Joseph Wheat & George A. Sarosi

  3. Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, 46202

    Mitchell Goldman & George A. Sarosi

Authors
  1. L. Joseph Wheat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mitchell Goldman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. George A. Sarosi
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Infectious Disease, Brigham & Women’s Hospital, Boston, Massachusetts

    Robert H. Rubin M.D (Associate Director) (Associate Director)

  2. Center for Experimental Pharmacology and Therapeutics, Harvard University-Massachusetts Institute of Technology Division of Health Sciences and Technology, Cambridge, Massachusetts

    Robert H. Rubin M.D (Associate Director) (Associate Director)

  3. Kuzell Institute for Arthritis and Infectious Diseases Chief of the Division on Infectious Diseases, Pacific California Medical Center, San Francisco, California

    Lowell S. Young M.D. (Director) (Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Kluwer Academic Publishers

About this chapter

Cite this chapter

Joseph Wheat, L., Goldman, M., Sarosi, G.A. (2002). Fungal Infections in the Immunocompromised Host. In: Rubin, R.H., Young, L.S., Van Furth, R. (eds) Clinical Approach to Infection in the Compromised Host. Springer, Boston, MA. https://doi.org/10.1007/0-306-47527-8_6

Download citation

  • DOI: https://doi.org/10.1007/0-306-47527-8_6

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-306-46693-9

  • Online ISBN: 978-0-306-47527-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation